Yahoo Finance

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

PONTE VEDRA, Fla., April 30, 2026 (GLOBE NEWSWIRE)-- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic ...
Hosted on MSN

CVKD: Designing phase 3 trial for CAD-1005 in HIT

Planning for Phase 3 Registration Trial of CAD-1005 in HIT On April 30, 2026, Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) announced an ‘End-of-Phase 2’ meeting with the U.S. Food and Drug ...
International Business Times

‘One Piece’ 1005 Spoilers: Tease Oda Finally Giving In To Fans’ Most-Requested Fight

"One Piece" Chapter 1005 is titled "Devil's Child" The upcoming manga is set to arrive Feb. 28 The most requested showdown between two interestingly powerful women might happen in "One Piece" Chapter ...
Nasdaq

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of ...
manilatimes

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 ...

Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in ...